Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Alpha-1 Anti-Trypsin Deficiency - Forecast in 9 Major Markets 2016-2026 - Research and Markets

Research and Markets
Posted on: 30 Sep 16

Research and Markets has announced the addition of the "Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026" report to their offering.

Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.

This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Reasons to Buy:

  • Able to quantify patient populations in the global Alpha-1 Anti-Trypsin market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Alpha-1 Anti-Trypsin and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on the Alpha-1 Anti-Trypsin prevalent population.
  • Identify sub-populations within Alpha-1 Anti-Trypsin which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Alpha-1 Anti-Trypsin patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions

8. Methodology for quantification of patient numbers

9. Top-line prevalence

10. Features of AATD patients

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/c2d28r/alpha1

View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005548/en/

Business Wire
www.businesswire.com

Last updated on: 30/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.